TY - JOUR
T1 - Adult-Onset Hypogonadism
AU - Khera, Mohit
AU - Broderick, Gregory A.
AU - Carson, Culley C.
AU - Dobs, Adrian S.
AU - Faraday, Martha M.
AU - Goldstein, Irwin
AU - Hakim, Lawrence S.
AU - Hellstrom, Wayne J.G.
AU - Kacker, Ravi
AU - Köhler, Tobias S.
AU - Mills, Jesse N.
AU - Miner, Martin
AU - Sadeghi-Nejad, Hossein
AU - Seftel, Allen D.
AU - Sharlip, Ira D.
AU - Winters, Stephen J.
AU - Burnett, Arthur L.
N1 - Funding Information:
Grant Support: The colloquium from which this manuscript originated was funded by a grant from the Sexual Medicine Society of North America (SMSNA) Foundation and an educational grant from Repros Therapeutics, Inc . The SMSNA required complete independence from industry during the development of this document. No industry representatives were present in the closed meeting, there was no industry participation in the evidence selection, discussion, or creation of this document, and there was no attempt by industry to influence its content.
Funding Information:
Potential Competing Interests: Dr Khera is a consultant for AbbVie, Endo Pharmaceuticals, Lipocine, and Repros Therapeutics, Inc. Dr Carson received grant support from Auxilium and is a consultant for AbbVie. Dr Dobs received grant support from the National Institutes of Health and Boehringer Pharmaceuticals. Dr Goldstein is on the advisory board of Lipocine and TesoRx and is involved in research with Endo, Lipocine, Repros, and TesoRx. Dr Hellstrom is a consultant for Endo, Repros Therapeutics, and Lipocine. Dr Kacker is founder/owner of MHB Labs. Dr Köhler is involved in research with and is a consultant for AbbVie and Lipocine. Dr Mills is a speaker for AbbVie. Dr Miner is a consultant for Lipocine and Repros Therapeutics. Dr Sadeghi-Nejad is a clinical research investigator for Endo. Dr Burnett is involved with Auxilium, AbbVie, and Lilly. The rest of the authors report no competing interests.
Publisher Copyright:
© 2016 The Authors
PY - 2016/7/1
Y1 - 2016/7/1
N2 - In August 2015, an expert colloquium commissioned by the Sexual Medicine Society of North America (SMSNA) convened in Washington, DC, to discuss the common clinical scenario of men who present with low testosterone (T) and associated signs and symptoms accompanied by low or normal gonadotropin levels. This syndrome is not classical primary (testicular failure) or secondary (pituitary or hypothalamic failure) hypogonadism because it may have elements of both presentations. The panel designated this syndrome adult-onset hypogonadism (AOH) because it occurs commonly in middle-age and older men. The SMSNA is a not-for-profit society established in 1994 to promote, encourage, and support the highest standards of practice, research, education, and ethics in the study of human sexual function and dysfunction. The panel consisted of 17 experts in men's health, sexual medicine, urology, endocrinology, and methodology. Participants declared potential conflicts of interest and were SMSNA members and nonmembers. The panel deliberated regarding a diagnostic process to document signs and symptoms of AOH, the rationale for T therapy, and a monitoring protocol for T-treated patients. The evaluation and management of hypogonadal syndromes have been addressed in recent publications (ie, the Endocrine Society, the American Urological Association, and the International Society for Sexual Medicine). The primary purpose of this document was to support health care professionals in the development of a deeper understanding of AOH, particularly in how it differs from classical primary and secondary hypogonadism, and to provide a conceptual framework to guide its diagnosis, treatment, and follow-up.
AB - In August 2015, an expert colloquium commissioned by the Sexual Medicine Society of North America (SMSNA) convened in Washington, DC, to discuss the common clinical scenario of men who present with low testosterone (T) and associated signs and symptoms accompanied by low or normal gonadotropin levels. This syndrome is not classical primary (testicular failure) or secondary (pituitary or hypothalamic failure) hypogonadism because it may have elements of both presentations. The panel designated this syndrome adult-onset hypogonadism (AOH) because it occurs commonly in middle-age and older men. The SMSNA is a not-for-profit society established in 1994 to promote, encourage, and support the highest standards of practice, research, education, and ethics in the study of human sexual function and dysfunction. The panel consisted of 17 experts in men's health, sexual medicine, urology, endocrinology, and methodology. Participants declared potential conflicts of interest and were SMSNA members and nonmembers. The panel deliberated regarding a diagnostic process to document signs and symptoms of AOH, the rationale for T therapy, and a monitoring protocol for T-treated patients. The evaluation and management of hypogonadal syndromes have been addressed in recent publications (ie, the Endocrine Society, the American Urological Association, and the International Society for Sexual Medicine). The primary purpose of this document was to support health care professionals in the development of a deeper understanding of AOH, particularly in how it differs from classical primary and secondary hypogonadism, and to provide a conceptual framework to guide its diagnosis, treatment, and follow-up.
UR - http://www.scopus.com/inward/record.url?scp=84991665776&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991665776&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2016.04.022
DO - 10.1016/j.mayocp.2016.04.022
M3 - Review article
C2 - 27343020
AN - SCOPUS:84991665776
SN - 0025-6196
VL - 91
SP - 908
EP - 926
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 7
ER -